Achieved Q4 2025 PEMGARDA® (pemivibart) net product revenue of $17.2 million, representing 25% growth year-over-year and 31% growth quarter-over-quarter 2025 year-end cash and cash equivalents of $226.7 million after raising over $200 million from financing transactions in 2H 2025 Announced initiation of DECLARATION Phase 3 pivotal clinical trial of vaccine-alternative antibody VYD2311 to prevent COVID, with top-line data expected mid-2026; Fast Track designation for VYD2311 granted by FDA in December 2025 DECLARATION trial on track with full enrollment achieved DECLARATION trial Independent Data Monitoring Committee (IDMC) prespecified review of unblinded VYD2311 safety data resulted in IDMC recommendation to allow enrollment of pregnant and breastfeeding women in the DECLARATION trial DECLARATION trial blinded, pooled early COVID event...

Fourth Quarter and Full Year Results Exceeded Top- and Bottom-line Guidance Comparable Sales Increased 8% in the Fourth Quarter and 5% for the Full Year Fourth Quarter and Full Year Adjusted Operating Income Significantly Exceeded Expectations Initiates First Quarter and Fiscal 2026 GuidanceREYNOLDSBURG, Ohio, March 05, 2026 (GLOBE NEWSWIRE) — Victoria’s Secret & Co. (“VS&Co” or the “Company”) (NYSE: VSCO) today reported financial results for the fourth quarter and fiscal year ended January 31, 2026. Hillary Super, VS&Co Chief Executive Officer, said, “We delivered an exceptional fourth quarter and a standout year, exceeding top- and bottom-line guidance with broad based outperformance across brands, channels and geographies. We drove meaningful acceleration in the second half of the year, with fourth quarter...

Dosing completed in Phase 1 study of budoprutug subcutaneous formulation, with data expected in H1 2026 Budoprutug clinical trials ongoing in pMN, ITP, and SLE, with initial data from all three trials expected in H2 2026 Enrollment ongoing in CLYM116 Phase 1 healthy volunteer study, with initial data expected mid-2026 Strong financial position with cash runway expected into 2028 WELLESLEY HILLS, Mass., March 05, 2026 (GLOBE NEWSWIRE) — Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business updates. “Throughout 2025, we translated strategy into disciplined execution and meaningfully advanced our pipeline,” said Aoife Brennan, M.B.,...

Q4 reported revenue of $157.9 million increased 2.8% and organic* revenue increased 10.0% Fourth quarter GAAP earnings of $0.21 per diluted share compared to $0.00 in the prior-year period Non-GAAP earnings* of $0.24 per diluted share Fourth quarter cash from operations of $38.0 million increased 97% 2026 financial guidance reflects continued above-market revenue growth, higher earnings and robust cash generationDURHAM, N.C., March 05, 2026 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced fourth quarter and full-year financial results for the year ended December 31, 2025, and provided its financial guidance for full-year 2026. “Our team delivered strong fourth quarter performance, concluding an important year in which we strengthened...

ATHENS, Greece, March 05, 2026 (GLOBE NEWSWIRE) — Capital Clean Energy Carriers Corp. (the “Company”, “CCEC”, “we” or “us”) (NASDAQ: CCEC), an international owner of ocean-going vessels, today released its financial results for the fourth quarter ended December 31, 2025. Key Quarterly HighlightsOrdered three latest-technology LNG carriers with deliveries in 2028 and 2029 Concluded the sale of a 13,696 TEU container vessel, the M/V Buenaventura Express Took delivery of our first LCO2/multi-gas carrier, the Active Announced dividend of $0.15 per share for the fourth quarter of 2025Key Financial Highlights (continuing operations)  Three-month period ended December 31,  2025 2024 Increase/(Decrease)Revenues $98.3 million $97.6 million 0.7%Expenses $44.8 million $44.5 million 0.7%Interest expense and finance cost $23.9...

Pivotal sotagliflozin milestones on schedule including resubmission of NDA in T1D and enrollment of SONATA study for HCM  Positive End-of-Phase 2 meeting with FDA for pilavapadin confirms Phase 3 readiness and supports ongoing partnership discussions Strengthened financial position with more than $100 million in additional cash from capital raise and Novo Nordisk milestone payment Conference call and webcast at 8:30 am ET   THE WOODLANDS, Texas, March 05, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months and year ended December 31, 2025, and provided an update on key corporate milestones and accomplishments.  “The fourth quarter of 2025 marked the completion of an incredible year for Lexicon,” said Mike Exton, Ph.D., Lexicon’s chief executive officer and...

LIBERTY, Mo., March 05, 2026 (GLOBE NEWSWIRE) — Ferrellgas Partners, L.P. (OTC: FGPR) (“Ferrellgas” or the “Company”) today reported financial results for its 2026 second fiscal quarter ended January 31, 2026. “Our team’s preparation at the beginning of fiscal 2026 enabled us to achieve strong second-quarter results,” said Tamria Zertuche, President and CEO. “Extended cold weather across much of the eastern region, combined with warmer conditions in the west, created both challenges and opportunities for the beginning of the winter heating season. Our employee-owners showed exceptional adaptability by reallocating personnel and resources to meet increased demand while continuing to drive growth and manage expenses. As a result, we achieved expanded margins, increased profit and are well positioned for the upcoming quarter and the...

NEW YORK, March 05, 2026 (GLOBE NEWSWIRE) — Teads Holding Co. (Nasdaq: TEAD) (“Teads” or the “Company”) announced today financial results for the quarter and full year ended December 31, 2025. Fourth Quarter and Full Year 2025 Key Financial Metrics1:  Three Months EndedDecember 31,   Twelve Months EndedDecember 31,(in millions USD)   2025       2024     % Change     2025       2024     % ChangeRevenue $ 352.2     $ 234.6     50 %   $ 1,300.5     $ 889.9     46 %Gross profit   120.4       56.1     115 %     429.1       192.1     123 %Net loss   (428.2 )     (0.2 )   NM     (517.1 )     (0.7 )   NMNet cash provided by operating activities   7.3       42.7     (83 )%     7.6       68.6     (89 )%                       Non-GAAP Financial Data*                      Ex-TAC gross profit   151.8       68.3     122 %     529.7       236.1     124 %Adjusted...

Achieved YUTREPIA® net product sales of $148.3 million for the full year 2025 with $90.1 million in the fourth quarter More than 3,600 unique prescriptions received and 2,900 patients treated to date since launch in June 2025 Ended 2025 with $190.7 million in cash and cash equivalents, an increase of $33.2 million from the third quarter Recorded second consecutive quarter of profitabilityMORRISVILLE, N.C., March 05, 2026 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today reported financial results for the full year ended December 31, 2025. The company will also host a webcast at 8:30 a.m. ET on March 5, 2026, to discuss its financial results and provide a corporate update. Dr....

Delivered 4% Y/Y Net Sales Growth Drove 34% Y/Y Bookings Growth in Fine JewelryProvides Q1 and Full Year Guidance 2026 SAN FRANCISCO, March 05, 2026 (GLOBE NEWSWIRE) — Brilliant Earth Group, Inc. (“Brilliant Earth” or the “Company”) (Nasdaq: BRLT), an innovative, global leader in ethically sourced fine jewelry, today announced financial results for the three and twelve months ended December 31, 2025. Fourth Quarter and Fiscal Year 2025 Highlights (quarterly and annual periods ended December 31, 2025):Delivered Net Sales of $124.4 million and $437.5 million in the fourth quarter and fiscal year, respectively.Largest quarter ever of Net Sales Total orders grew year-over-year 7% in Q4 and 13% in 2025 Repeat orders grew year-over-year 15% in Q4 and 13% in 2025 Average Selling Price (ASP) grew year-over-year across the assortment...